11 Amendments of Andreas MÖLZER related to 2010/2153(INI)
Amendment 21 #
Motion for a resolution
Recital B
Recital B
B. whereas the criteria for defining a ‘pandemic’, adopted by the WHO in 2009 and based solely on the propagation of the virus while discounting the severity of the infection, - in contrast to earlier definitions, based on high morbidity and mortality rates - distorted the meaning of the word ‘pandemic’ and triggered a false alarm worldwide, with that alarmism giving rise to inappropriate public health decisions and a disproportionate response among the public and administrations of the European Union and its Member States,
Amendment 49 #
Motion for a resolution
Recital E a (new)
Recital E a (new)
Ea. whereas Poland's decision not to order or offer vaccinations against H1N1 influenza did not significantly increase the mortality rate in that country,
Amendment 66 #
Motion for a resolution
Recital I a (new)
Recital I a (new)
Ia. whereas in that connection the influence exerted on the WHO and the EU by lobbyists working on behalf of international pharmaceuticals companies should be examined more closely,
Amendment 94 #
Motion for a resolution
Paragraph 2
Paragraph 2
2. Takes the view that the powers of and funding for the European Centre for Disease Prevention and Control (ECDC) should be reinforced so that the EU has its own means of assessing the severity of infection risk, by establishing, if necessary, its own health alert scale independent of international organisations such as the WHO;
Amendment 99 #
Motion for a resolution
Paragraph 3
Paragraph 3
3. Demands that robust, credible, independent, quick and effective scientific procedures be introduced for the evaluation of medicinal products recommended in the event of health emergencies, and more particularly in genuine pandemic situations;
Amendment 108 #
Motion for a resolution
Paragraph 4
Paragraph 4
4. Calls for immediate independent data collection and corresponding clarifications on the effectiveness of the influenza vaccination strategies recommended in the EU, given the weight of evidence casting doubt on their effectiveness, the absence of reliable data guaranteeing that effectiveness and the lingering uncertainties surrounding their benefit-risk profile;
Amendment 115 #
Motion for a resolution
Paragraph 5
Paragraph 5
5. Calls in particular on the EMA to review the accelerated authorisation procedures for the placing on the market of medicinal products designed to respond to a health crisis, in order to ensure correct assessment of the benefit-risk profile associated with the use of those medicinal products, and to draw up corresponding proposals for a revision of these authorisation procedures;
Amendment 136 #
Motion for a resolution
Paragraph 8
Paragraph 8
8. Considers the conflicts of interest apparent in the case of some experts who advise the European institutions to give rise to suspicions of undue influence and to undermine the overall credibility of the European health agencies and their recommendations; calls in particular for the EMA and ECDC to revise forthwith their current and future expert screening procedures to ensure complete transparency; calls on the European Anti- Fraud Office (OLAF) to carry out a thoroughgoing review of these screening procedures;
Amendment 140 #
Motion for a resolution
Paragraph 9
Paragraph 9
9. Calls for the publication of the names, roles and potential conflicts of interest of senior officials who are members of informal groups such as the EU’s Health Security Committee, the Health Emergency Operational Facility (HEOF) and the ‘vaccines’ task force; calls on OLAF to investigate these statements concerning the falsification of or the failure to provide important information;
Amendment 167 #
Motion for a resolution
Paragraph 12
Paragraph 12
12. Expresses its approval of the introduction of a procedure enabling the Member States to make group purchases of anti-viral vaccines and medicinal products on a voluntary basis where the positive benefit-risk profile of their preventive/therapeutic effect is clearly demonstrated by independent experts and indisputable, in order to obtain, for a given product, advantageous rates approaching its cost price;
Amendment 172 #
Motion for a resolution
Paragraph 14
Paragraph 14
14. Instructs its President to forward this resolution to the Council, the Commission, the WHO and national parliaments.